Andrew Donson
Concepts (433)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ependymoma | 29 | 2026 | 176 | 5.580 |
Why?
| | Brain Neoplasms | 46 | 2026 | 1318 | 4.240 |
Why?
| | Infratentorial Neoplasms | 9 | 2026 | 71 | 2.480 |
Why?
| | Glioma | 19 | 2026 | 425 | 2.250 |
Why?
| | Medulloblastoma | 16 | 2025 | 215 | 1.690 |
Why?
| | Astrocytoma | 13 | 2025 | 129 | 1.540 |
Why?
| | Gene Expression Regulation, Neoplastic | 27 | 2025 | 1455 | 1.480 |
Why?
| | Craniopharyngioma | 7 | 2024 | 77 | 1.330 |
Why?
| | Glioblastoma | 14 | 2019 | 353 | 1.330 |
Why?
| | Rhabdoid Tumor | 12 | 2025 | 103 | 1.320 |
Why?
| | Cerebellar Neoplasms | 10 | 2025 | 177 | 1.280 |
Why?
| | Brain Stem Neoplasms | 9 | 2023 | 87 | 1.280 |
Why?
| | Gene Expression Profiling | 26 | 2024 | 1782 | 1.220 |
Why?
| | Pituitary Neoplasms | 5 | 2024 | 190 | 1.020 |
Why?
| | Biomarkers, Tumor | 14 | 2026 | 1313 | 1.000 |
Why?
| | Ganglioglioma | 5 | 2025 | 34 | 0.960 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2025 | 225 | 0.870 |
Why?
| | Central Nervous System Neoplasms | 9 | 2021 | 173 | 0.860 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2026 | 1137 | 0.720 |
Why?
| | Cell Line, Tumor | 29 | 2025 | 3539 | 0.700 |
Why?
| | Drug Screening Assays, Antitumor | 5 | 2021 | 191 | 0.690 |
Why?
| | Teratoma | 7 | 2025 | 120 | 0.670 |
Why?
| | Radiation Tolerance | 7 | 2025 | 103 | 0.670 |
Why?
| | Transcriptome | 12 | 2025 | 1044 | 0.660 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 81 | 0.610 |
Why?
| | Single-Cell Analysis | 3 | 2025 | 356 | 0.580 |
Why?
| | Child | 52 | 2026 | 22537 | 0.580 |
Why?
| | Neoplasms, Neuroepithelial | 3 | 2026 | 14 | 0.570 |
Why?
| | Supratentorial Neoplasms | 3 | 2026 | 18 | 0.550 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2026 | 210 | 0.540 |
Why?
| | Cyst Fluid | 1 | 2017 | 20 | 0.530 |
Why?
| | Tumor Suppressor Proteins | 3 | 2026 | 321 | 0.530 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 732 | 0.520 |
Why?
| | Antineoplastic Agents | 7 | 2022 | 2192 | 0.500 |
Why?
| | Oligonucleotide Array Sequence Analysis | 19 | 2016 | 758 | 0.480 |
Why?
| | Humans | 110 | 2026 | 144261 | 0.480 |
Why?
| | Radiation | 3 | 2021 | 24 | 0.480 |
Why?
| | Cell Cycle Proteins | 6 | 2022 | 628 | 0.450 |
Why?
| | Child, Preschool | 33 | 2026 | 11774 | 0.440 |
Why?
| | DNA Methylation | 8 | 2026 | 681 | 0.440 |
Why?
| | Chromosomes, Human, Pair 1 | 3 | 2020 | 78 | 0.440 |
Why?
| | Nuclear Proteins | 5 | 2025 | 748 | 0.430 |
Why?
| | SMARCB1 Protein | 3 | 2025 | 34 | 0.420 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2025 | 881 | 0.420 |
Why?
| | Cancer Vaccines | 2 | 2010 | 160 | 0.410 |
Why?
| | Prognosis | 18 | 2026 | 4278 | 0.400 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2026 | 1953 | 0.360 |
Why?
| | Cell Proliferation | 18 | 2025 | 2494 | 0.360 |
Why?
| | Radiation-Sensitizing Agents | 3 | 2016 | 43 | 0.360 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2026 | 339 | 0.350 |
Why?
| | Cytokines | 4 | 2018 | 2061 | 0.350 |
Why?
| | Epigenesis, Genetic | 5 | 2025 | 684 | 0.350 |
Why?
| | Apoptosis | 15 | 2025 | 2430 | 0.350 |
Why?
| | Neoplasm Proteins | 3 | 2012 | 442 | 0.340 |
Why?
| | Tumor Cells, Cultured | 10 | 2025 | 919 | 0.340 |
Why?
| | Survivors | 2 | 2023 | 516 | 0.320 |
Why?
| | Chromosome Aberrations | 2 | 2023 | 162 | 0.310 |
Why?
| | Chromatin | 5 | 2026 | 561 | 0.310 |
Why?
| | Mutation | 9 | 2025 | 4085 | 0.310 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2019 | 433 | 0.300 |
Why?
| | Histones | 4 | 2021 | 668 | 0.290 |
Why?
| | Proto-Oncogene Proteins | 5 | 2022 | 623 | 0.290 |
Why?
| | Microarray Analysis | 7 | 2017 | 117 | 0.290 |
Why?
| | Quinazolines | 3 | 2022 | 266 | 0.290 |
Why?
| | Pyrimidines | 6 | 2017 | 532 | 0.270 |
Why?
| | Infant | 19 | 2026 | 10022 | 0.270 |
Why?
| | MAP Kinase Signaling System | 2 | 2021 | 309 | 0.270 |
Why?
| | NF-kappa B | 3 | 2025 | 661 | 0.260 |
Why?
| | DNA Modification Methylases | 1 | 2007 | 18 | 0.260 |
Why?
| | Cell Differentiation | 6 | 2026 | 2048 | 0.260 |
Why?
| | DNA Repair Enzymes | 1 | 2007 | 29 | 0.250 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 237 | 0.250 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2007 | 72 | 0.250 |
Why?
| | Dacarbazine | 1 | 2007 | 100 | 0.250 |
Why?
| | Mice | 18 | 2026 | 18329 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 6 | 2 | 2020 | 49 | 0.240 |
Why?
| | Chromosomes | 2 | 2024 | 108 | 0.240 |
Why?
| | Female | 42 | 2026 | 77976 | 0.240 |
Why?
| | Immunohistochemistry | 6 | 2017 | 1715 | 0.240 |
Why?
| | Adolescent | 25 | 2026 | 22281 | 0.240 |
Why?
| | Male | 40 | 2026 | 72035 | 0.240 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 241 | 0.230 |
Why?
| | Trastuzumab | 1 | 2026 | 118 | 0.230 |
Why?
| | Chloroquine | 2 | 2017 | 53 | 0.230 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.230 |
Why?
| | RNA, Messenger | 8 | 2017 | 2829 | 0.230 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2026 | 161 | 0.220 |
Why?
| | Transcription Factors | 6 | 2026 | 1739 | 0.220 |
Why?
| | Sirtuin 2 | 1 | 2025 | 27 | 0.220 |
Why?
| | Kaplan-Meier Estimate | 5 | 2021 | 964 | 0.220 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 163 | 0.220 |
Why?
| | Cell Cycle | 9 | 2025 | 596 | 0.210 |
Why?
| | Cisplatin | 3 | 2016 | 334 | 0.210 |
Why?
| | Immunophenotyping | 2 | 2017 | 322 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2025 | 193 | 0.210 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 431 | 0.210 |
Why?
| | Cellular Senescence | 2 | 2024 | 226 | 0.210 |
Why?
| | Neoplasms, Radiation-Induced | 3 | 2010 | 99 | 0.210 |
Why?
| | Neurofibroma, Plexiform | 1 | 2023 | 12 | 0.200 |
Why?
| | Phagocytosis | 1 | 2025 | 299 | 0.200 |
Why?
| | Cell Lineage | 2 | 2026 | 376 | 0.200 |
Why?
| | Neurofibromatosis 1 | 1 | 2023 | 54 | 0.190 |
Why?
| | Animals | 20 | 2026 | 38030 | 0.190 |
Why?
| | Autophagy | 2 | 2017 | 285 | 0.190 |
Why?
| | Nerve Net | 1 | 2026 | 285 | 0.190 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2021 | 54 | 0.190 |
Why?
| | DNA-Binding Proteins | 4 | 2026 | 1497 | 0.190 |
Why?
| | Pyrazoles | 5 | 2022 | 509 | 0.190 |
Why?
| | Survival Analysis | 3 | 2023 | 1382 | 0.190 |
Why?
| | Tamoxifen | 2 | 2004 | 217 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2025 | 167 | 0.180 |
Why?
| | Cell Survival | 8 | 2020 | 1098 | 0.180 |
Why?
| | raf Kinases | 1 | 2021 | 11 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 14 | 0.180 |
Why?
| | Survival Rate | 6 | 2026 | 2088 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.170 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 412 | 0.170 |
Why?
| | Indoles | 2 | 2017 | 501 | 0.170 |
Why?
| | Sulfonamides | 2 | 2017 | 580 | 0.170 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 73 | 0.170 |
Why?
| | Receptor, ErbB-3 | 2 | 2015 | 48 | 0.170 |
Why?
| | Vaccination | 1 | 2010 | 1422 | 0.170 |
Why?
| | Receptor, trkC | 1 | 2021 | 10 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2023 | 219 | 0.170 |
Why?
| | Gene Amplification | 1 | 2021 | 120 | 0.170 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2021 | 69 | 0.170 |
Why?
| | Receptor, trkB | 1 | 2021 | 36 | 0.170 |
Why?
| | Cohort Studies | 9 | 2021 | 5935 | 0.170 |
Why?
| | Gene Expression | 4 | 2015 | 1487 | 0.160 |
Why?
| | Follow-Up Studies | 8 | 2026 | 5389 | 0.160 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 64 | 0.160 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 66 | 0.160 |
Why?
| | B7 Antigens | 1 | 2020 | 18 | 0.160 |
Why?
| | Anilides | 2 | 2010 | 84 | 0.160 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 91 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 154 | 0.150 |
Why?
| | Phenotype | 5 | 2024 | 3157 | 0.150 |
Why?
| | Pons | 2 | 2026 | 33 | 0.150 |
Why?
| | MicroRNAs | 2 | 2020 | 700 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 981 | 0.150 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2025 | 70 | 0.150 |
Why?
| | Genome, Human | 3 | 2021 | 422 | 0.150 |
Why?
| | Pteridines | 2 | 2016 | 22 | 0.140 |
Why?
| | Protein Kinase C | 1 | 2000 | 252 | 0.140 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 496 | 0.140 |
Why?
| | Infant, Newborn | 8 | 2020 | 6424 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 585 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2017 | 2026 | 0.140 |
Why?
| | Epigenomics | 3 | 2026 | 114 | 0.140 |
Why?
| | ErbB Receptors | 2 | 2015 | 627 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1519 | 0.140 |
Why?
| | Meningioma | 2 | 2009 | 86 | 0.140 |
Why?
| | Adenoviridae | 1 | 1998 | 199 | 0.130 |
Why?
| | Stromal Cells | 1 | 2018 | 124 | 0.130 |
Why?
| | Drug Approval | 1 | 2018 | 89 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 529 | 0.130 |
Why?
| | SOXE Transcription Factors | 2 | 2016 | 22 | 0.130 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 85 | 0.130 |
Why?
| | Computer Simulation | 2 | 2021 | 1025 | 0.130 |
Why?
| | Macrophages | 1 | 2025 | 1510 | 0.130 |
Why?
| | Genes, p16 | 1 | 2017 | 13 | 0.130 |
Why?
| | Aging | 2 | 2020 | 1964 | 0.130 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 47 | 0.130 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 55 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 111 | 0.130 |
Why?
| | E2F Transcription Factors | 1 | 2017 | 62 | 0.130 |
Why?
| | Young Adult | 10 | 2026 | 13990 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 128 | 0.130 |
Why?
| | Spinal Neoplasms | 1 | 2017 | 36 | 0.130 |
Why?
| | Stem Cells | 1 | 2021 | 625 | 0.120 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.120 |
Why?
| | Genetic Therapy | 1 | 1998 | 313 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 264 | 0.120 |
Why?
| | Blotting, Western | 6 | 2013 | 1187 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 905 | 0.120 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 780 | 0.120 |
Why?
| | Myeloid Cells | 2 | 2015 | 148 | 0.120 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2019 | 142 | 0.120 |
Why?
| | EGF Family of Proteins | 1 | 2015 | 17 | 0.110 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 16 | 0.110 |
Why?
| | Retrospective Studies | 11 | 2020 | 17009 | 0.110 |
Why?
| | Receptor, EphA2 | 1 | 2015 | 17 | 0.110 |
Why?
| | Neuroectodermal Tumors, Primitive | 2 | 2012 | 10 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 436 | 0.110 |
Why?
| | Flow Cytometry | 3 | 2006 | 1172 | 0.110 |
Why?
| | Pilomatrixoma | 1 | 2015 | 3 | 0.110 |
Why?
| | Brain | 2 | 2026 | 2930 | 0.110 |
Why?
| | Proteins | 1 | 2021 | 1021 | 0.110 |
Why?
| | Radiation, Ionizing | 2 | 2012 | 87 | 0.110 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4556 | 0.110 |
Why?
| | Mutation, Missense | 1 | 2016 | 340 | 0.110 |
Why?
| | src-Family Kinases | 1 | 2015 | 93 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 982 | 0.110 |
Why?
| | Adult | 17 | 2026 | 40262 | 0.110 |
Why?
| | Activin Receptors, Type I | 1 | 2014 | 6 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 928 | 0.100 |
Why?
| | Drug Delivery Systems | 2 | 2015 | 379 | 0.100 |
Why?
| | Deoxyribose | 1 | 2013 | 6 | 0.100 |
Why?
| | Glutamate-Cysteine Ligase | 1 | 2013 | 20 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 207 | 0.100 |
Why?
| | Acetylcysteine | 1 | 2013 | 138 | 0.090 |
Why?
| | Karyotyping | 4 | 2010 | 106 | 0.090 |
Why?
| | Karnofsky Performance Status | 1 | 2012 | 37 | 0.090 |
Why?
| | RNA-Binding Proteins | 2 | 2015 | 462 | 0.090 |
Why?
| | Exons | 1 | 2013 | 358 | 0.090 |
Why?
| | Receptors, Opioid | 1 | 2012 | 23 | 0.090 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1264 | 0.090 |
Why?
| | Central Nervous System | 1 | 2014 | 281 | 0.090 |
Why?
| | Protein Precursors | 1 | 2012 | 136 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2730 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3313 | 0.080 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 634 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2015 | 780 | 0.080 |
Why?
| | Acetaminophen | 1 | 2013 | 264 | 0.080 |
Why?
| | Drug Synergism | 3 | 2017 | 357 | 0.080 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2011 | 177 | 0.080 |
Why?
| | Databases, Factual | 1 | 2016 | 1484 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 3 | 2014 | 968 | 0.080 |
Why?
| | Cluster Analysis | 3 | 2021 | 519 | 0.080 |
Why?
| | Risk Factors | 4 | 2020 | 10699 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 220 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 307 | 0.080 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2009 | 19 | 0.080 |
Why?
| | Spinal Cord Neoplasms | 1 | 2009 | 40 | 0.080 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2009 | 86 | 0.070 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1982 | 0.070 |
Why?
| | Astrocytes | 1 | 2011 | 222 | 0.070 |
Why?
| | Hemangioma | 1 | 2009 | 46 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3857 | 0.070 |
Why?
| | Signal Transduction | 3 | 2025 | 5221 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1322 | 0.070 |
Why?
| | Gene Ontology | 2 | 2021 | 53 | 0.070 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 824 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 412 | 0.070 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 102 | 0.070 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2010 | 230 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1046 | 0.070 |
Why?
| | Herpesvirus 3, Human | 1 | 2011 | 336 | 0.070 |
Why?
| | Herpes Zoster | 1 | 2011 | 315 | 0.070 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 183 | 0.060 |
Why?
| | Meningeal Neoplasms | 1 | 2008 | 93 | 0.060 |
Why?
| | Mesenchymoma | 1 | 2007 | 10 | 0.060 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 13 | 0.060 |
Why?
| | Phosphorylation | 3 | 2017 | 1732 | 0.060 |
Why?
| | Aurora Kinases | 3 | 2012 | 28 | 0.060 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2012 | 341 | 0.060 |
Why?
| | Thymidine | 1 | 2006 | 60 | 0.060 |
Why?
| | Etoposide | 1 | 2007 | 166 | 0.060 |
Why?
| | Aurora Kinase A | 3 | 2012 | 62 | 0.060 |
Why?
| | High Mobility Group Proteins | 1 | 2006 | 45 | 0.060 |
Why?
| | Injections, Spinal | 1 | 2026 | 120 | 0.060 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2012 | 140 | 0.060 |
Why?
| | Prosencephalon | 1 | 2026 | 53 | 0.060 |
Why?
| | Gene Silencing | 1 | 2007 | 205 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 592 | 0.060 |
Why?
| | Clone Cells | 1 | 2026 | 266 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.060 |
Why?
| | Piperazines | 2 | 2022 | 380 | 0.060 |
Why?
| | Azepines | 2 | 2019 | 107 | 0.060 |
Why?
| | Middle Aged | 8 | 2026 | 35762 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2012 | 322 | 0.050 |
Why?
| | Fatal Outcome | 2 | 2021 | 307 | 0.050 |
Why?
| | Coculture Techniques | 2 | 2011 | 246 | 0.050 |
Why?
| | Thalamus | 1 | 2026 | 125 | 0.050 |
Why?
| | Cell Division | 2 | 2010 | 766 | 0.050 |
Why?
| | Pyrimidinones | 2 | 2016 | 126 | 0.050 |
Why?
| | Computational Biology | 2 | 2020 | 680 | 0.050 |
Why?
| | Benzamides | 2 | 2017 | 224 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 13 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2024 | 11643 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 56 | 0.050 |
Why?
| | RNA, Small Nuclear | 1 | 2023 | 38 | 0.050 |
Why?
| | Trans-Activators | 1 | 2026 | 405 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 85 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2023 | 39 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 235 | 0.050 |
Why?
| | Caspases | 1 | 2004 | 232 | 0.050 |
Why?
| | Up-Regulation | 2 | 2016 | 851 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 3166 | 0.050 |
Why?
| | Cytidine Deaminase | 1 | 2023 | 59 | 0.050 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2004 | 194 | 0.050 |
Why?
| | Genomics | 2 | 2021 | 833 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2009 | 1165 | 0.050 |
Why?
| | Brain Stem | 1 | 2023 | 95 | 0.050 |
Why?
| | Synapses | 1 | 2026 | 439 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2016 | 824 | 0.050 |
Why?
| | RNA | 2 | 2023 | 939 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2021 | 1495 | 0.040 |
Why?
| | Septum Pellucidum | 1 | 2021 | 5 | 0.040 |
Why?
| | Cerebellum | 1 | 2023 | 223 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1983 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 14 | 0.040 |
Why?
| | Histone Deacetylases | 1 | 2023 | 210 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 673 | 0.040 |
Why?
| | Mesencephalon | 1 | 2021 | 64 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2021 | 124 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2013 | 194 | 0.040 |
Why?
| | Disease Progression | 2 | 2023 | 2840 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 918 | 0.040 |
Why?
| | Genetic Heterogeneity | 1 | 2021 | 62 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 58 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1461 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 197 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 155 | 0.040 |
Why?
| | DNA Damage | 2 | 2016 | 428 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 187 | 0.040 |
Why?
| | Vinblastine | 1 | 2020 | 75 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 148 | 0.040 |
Why?
| | Cell Fusion | 1 | 2020 | 49 | 0.040 |
Why?
| | Aged | 5 | 2026 | 25850 | 0.040 |
Why?
| | Carboplatin | 1 | 2020 | 160 | 0.040 |
Why?
| | Signal-To-Noise Ratio | 1 | 2020 | 73 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2023 | 437 | 0.040 |
Why?
| | RNA, Neoplasm | 2 | 2009 | 86 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1998 | 37 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2019 | 53 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1129 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 188 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2000 | 402 | 0.040 |
Why?
| | Odontogenesis | 1 | 2018 | 11 | 0.030 |
Why?
| | Laser Capture Microdissection | 1 | 2018 | 29 | 0.030 |
Why?
| | Lysine | 1 | 2020 | 302 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1047 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 83 | 0.030 |
Why?
| | Treatment Failure | 1 | 1999 | 363 | 0.030 |
Why?
| | Pyridines | 2 | 2012 | 605 | 0.030 |
Why?
| | Down-Regulation | 1 | 2000 | 627 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 23 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 63 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 22 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 33 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2018 | 370 | 0.030 |
Why?
| | Immune System | 1 | 1998 | 179 | 0.030 |
Why?
| | Pituitary Gland | 1 | 2018 | 148 | 0.030 |
Why?
| | Interleukin-2 | 1 | 1998 | 437 | 0.030 |
Why?
| | Triazoles | 1 | 2019 | 184 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1998 | 337 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2020 | 744 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 682 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 117 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 582 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 139 | 0.030 |
Why?
| | Neuroglia | 1 | 2018 | 172 | 0.030 |
Why?
| | Cetuximab | 1 | 2017 | 111 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 123 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.030 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1487 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 50 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 140 | 0.030 |
Why?
| | Immune Tolerance | 1 | 1998 | 379 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 549 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 321 | 0.030 |
Why?
| | Urea | 1 | 2016 | 84 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2182 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1998 | 388 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 128 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 304 | 0.030 |
Why?
| | Antigens, CD | 1 | 1998 | 555 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 382 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 442 | 0.030 |
Why?
| | Amphiregulin | 1 | 2015 | 27 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1998 | 1367 | 0.030 |
Why?
| | Gene Fusion | 1 | 2015 | 29 | 0.030 |
Why?
| | Mitosis | 1 | 2016 | 199 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 375 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 650 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 87 | 0.030 |
Why?
| | Gene Dosage | 1 | 2015 | 148 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 768 | 0.030 |
Why?
| | Inhibitor of Differentiation Protein 2 | 1 | 2014 | 5 | 0.030 |
Why?
| | Inhibitor of Differentiation Protein 1 | 1 | 2014 | 8 | 0.030 |
Why?
| | Smad Proteins | 1 | 2014 | 42 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2013 | 76 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2013 | 75 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 582 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 143 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 330 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1255 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2015 | 343 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2013 | 220 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1834 | 0.020 |
Why?
| | Catalysis | 1 | 2013 | 322 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 538 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 427 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 508 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3403 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4562 | 0.020 |
Why?
| | Glutathione | 1 | 2013 | 375 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 147 | 0.020 |
Why?
| | Acetylation | 1 | 2011 | 252 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 476 | 0.020 |
Why?
| | Neural Stem Cells | 1 | 2012 | 166 | 0.020 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2010 | 37 | 0.020 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2009 | 8 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5988 | 0.020 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 11 | 0.020 |
Why?
| | Papilloma | 1 | 2009 | 49 | 0.020 |
Why?
| | Kinetics | 1 | 2013 | 1627 | 0.020 |
Why?
| | Zebrafish | 1 | 2014 | 528 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2009 | 85 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 53 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2010 | 336 | 0.020 |
Why?
| | Antibodies, Neoplasm | 1 | 2009 | 34 | 0.020 |
Why?
| | Claudins | 1 | 2009 | 23 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 311 | 0.020 |
Why?
| | Epilepsy | 1 | 2013 | 375 | 0.020 |
Why?
| | Cytogenetics | 1 | 2008 | 11 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 573 | 0.020 |
Why?
| | Virus Replication | 1 | 2011 | 529 | 0.020 |
Why?
| | DNA Repair | 1 | 2009 | 255 | 0.020 |
Why?
| | Paresis | 1 | 2007 | 30 | 0.020 |
Why?
| | Biopsy | 1 | 2010 | 1075 | 0.020 |
Why?
| | Hypothalamic Neoplasms | 1 | 2006 | 9 | 0.020 |
Why?
| | Craniotomy | 1 | 2007 | 82 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 415 | 0.020 |
Why?
| | Inflammation | 1 | 2018 | 2877 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 203 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2143 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2006 | 273 | 0.010 |
Why?
| | Genetic Markers | 1 | 2006 | 331 | 0.010 |
Why?
| | Neural Crest | 1 | 2006 | 126 | 0.010 |
Why?
| | Vision Disorders | 1 | 2007 | 178 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 371 | 0.010 |
Why?
| | Caspase 3 | 1 | 2004 | 238 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 765 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8243 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2006 | 2359 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 7155 | 0.010 |
Why?
| | Neoplasms | 1 | 2008 | 2870 | 0.010 |
Why?
|
|
Donson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|